DE60040136D1 - Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion - Google Patents

Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion

Info

Publication number
DE60040136D1
DE60040136D1 DE60040136T DE60040136T DE60040136D1 DE 60040136 D1 DE60040136 D1 DE 60040136D1 DE 60040136 T DE60040136 T DE 60040136T DE 60040136 T DE60040136 T DE 60040136T DE 60040136 D1 DE60040136 D1 DE 60040136D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
proteins
hiv infection
chimeric protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60040136T
Other languages
German (de)
English (en)
Inventor
Edward A Berger
Castillo Christie M Del
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government Of United States, Us
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Application granted granted Critical
Publication of DE60040136D1 publication Critical patent/DE60040136D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60040136T 1999-03-16 2000-03-16 Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion Expired - Lifetime DE60040136D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12468199P 1999-03-16 1999-03-16
PCT/US2000/006946 WO2000055207A1 (en) 1999-03-16 2000-03-16 A novel chimeric protein for prevention and treatment of hiv infection

Publications (1)

Publication Number Publication Date
DE60040136D1 true DE60040136D1 (de) 2008-10-16

Family

ID=22416252

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040136T Expired - Lifetime DE60040136D1 (de) 1999-03-16 2000-03-16 Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion

Country Status (8)

Country Link
EP (1) EP1161455B1 (https=)
JP (1) JP2002538814A (https=)
AT (1) ATE407146T1 (https=)
AU (1) AU765218B2 (https=)
CA (1) CA2361292C (https=)
DE (1) DE60040136D1 (https=)
ES (1) ES2313886T3 (https=)
WO (1) WO2000055207A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925966D0 (en) 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
IL141023A0 (en) * 2001-01-22 2002-02-10 Gavish Galilee Bio Appl Ltd Recombinant polypeptides for effective hiv neutralization
US20030082630A1 (en) * 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2003040311A2 (en) 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
WO2003095492A1 (en) 2002-05-06 2003-11-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2484930A1 (en) 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
ES2319838B1 (es) * 2006-09-29 2010-02-11 Consejo Superior Investig. Cientificas Uso de inhibidores de la actividad de la proteina filamina a, para la elaboracion de composiciones farmaceuticas, compuestos inhibidores de dicha actividad, composiciones farmaceuticas y sus aplicaciones terapeuticas y procedimiento identificacion de dichos compuestos inhibidores.
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
EP3303373B1 (en) * 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP4004049A1 (en) * 2019-07-24 2022-06-01 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0956044A4 (en) * 1996-06-14 2005-01-05 Progenics Pharm Inc USES OF A CHEMOKIN RECEPTOR TO INHIBIT HIV-1 INFECTION
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A

Also Published As

Publication number Publication date
ES2313886T3 (es) 2009-03-16
EP1161455B1 (en) 2008-09-03
CA2361292C (en) 2012-05-29
CA2361292A1 (en) 2000-09-21
ATE407146T1 (de) 2008-09-15
AU765218B2 (en) 2003-09-11
WO2000055207A1 (en) 2000-09-21
EP1161455A1 (en) 2001-12-12
JP2002538814A (ja) 2002-11-19
AU3889600A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
ATE407146T1 (de) Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
MEP32008A (en) Specific binding agents of human angiopoietin-2
WO2022204316A3 (en) Variant nucleic acid libraries for cd3
AR068566A1 (es) Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
HRP20090527T1 (hr) Imunoglobulini za neutraliziranje nogo-a, namijenjeni liječenju neuroloških bolesti
BRPI0214137B8 (pt) anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
ATE470712T1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
DE60223340D1 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
WO2003034903A3 (en) Psma antibodies and protein multimers
DE602004023724D1 (de) Verfahren zur chemischen synthese chimärischer immunglobulinproteine
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
CY1109423T1 (el) Ανθρωπινα μονοκλωνα αντισωματα αντι-ιντελευκινης-5 και μεθοδοι και συνθεσεις που τα περιεχουν
ATE375999T1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
EP1064403A4 (en) ANTISENSE MODULATION BY PECAM-1
BR9815367A (pt) Sequências de aminoácidos para terapia e profilaxia de doenças através da toxina clostridium difficile
ES2098274T3 (es) Anticuerpos monoclonales.
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
CO5280147A1 (es) Anticuerpo humano monoclonal
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, US

8364 No opposition during term of opposition